Multidisciplinary Cancer Investigation
Thu, Oct 8, 2026
[Archive]
Volume 0 - Multidisciplinary Cancer Investigation
Multidiscip Cancer Investig 2025, 0 - Multidisciplinary Cancer Investigation: 60-63 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Moghadam S, Shakeri M, Olfatbakhsh A, Mirzaei H, Sheikhi Z, Khosravi M, et al . Free fatty acids fingerprinting profile of serum from different molecular subtypes of non-metastatic breast cancer using GC-FID: a pilot study. Multidiscip Cancer Investig 2025;
URL: http://mcijournal.com/article-1-426-en.html
URL: http://mcijournal.com/article-1-426-en.html
Shiva Moghadam1 
, Marzieh Shakeri2 , Asiie Olfatbakhsh1 , Hamed Mirzaei3 , Zahra Sheikhi4 , Mahdieh Khosravi3 , Hassan Rezadoost2 , Kambiz Gilany *5 
, Marzieh Shakeri2 , Asiie Olfatbakhsh1 , Hamed Mirzaei3 , Zahra Sheikhi4 , Mahdieh Khosravi3 , Hassan Rezadoost2 , Kambiz Gilany *5
1- Breast Diseases Group, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
2- Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran
3- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
4- Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
5- Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. ,kambiz.gilany@gmail.com
2- Department of Phytochemistry, Medicinal Plants and Drugs Research Institute, Shahid Beheshti University, Tehran, Iran
3- Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
4- Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
5- Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. ,
Abstract: (1043 Views)
Background: Recent studies indicate that unusual metabolism of fatty acids is strongly associated with breast cancer (BC), offering promising evidence for finding potential BC biomarkers. This research aims to characterize serum free fatty acid (FFA) metabolic profiles and to explore possible diagnostic biomarkers for breast cancer.
Methods: In this pilot study, 12 samples were analyzed, three per breast cancer molecular subtype. Using gas chromatography with a flame ionization detector (GC-FID), we analyzed FFA fingerprint profiles across different molecular subtypes of BC. Based on existing literature, we focused on four key FFAs: linoleic acid (C18:2), stearic acid (C18:0), palmitic acid (C16:0), and oleic acid (C18:1c).
Results: Our results suggest that serum FFA fingerprinting has strong potential to distinguish between breast cancer molecular subtypes, supporting its promise as a non-invasive diagnostic approach.
Conclusion: In this study, we show for the first time that potential application of free fatty acids fingerprinting profile of serum from breast cancer molecular subtypes using GC-FID.
Methods: In this pilot study, 12 samples were analyzed, three per breast cancer molecular subtype. Using gas chromatography with a flame ionization detector (GC-FID), we analyzed FFA fingerprint profiles across different molecular subtypes of BC. Based on existing literature, we focused on four key FFAs: linoleic acid (C18:2), stearic acid (C18:0), palmitic acid (C16:0), and oleic acid (C18:1c).
Results: Our results suggest that serum FFA fingerprinting has strong potential to distinguish between breast cancer molecular subtypes, supporting its promise as a non-invasive diagnostic approach.
Conclusion: In this study, we show for the first time that potential application of free fatty acids fingerprinting profile of serum from breast cancer molecular subtypes using GC-FID.
Keywords: Breast cancer molecular subtypes, Free fatty acids (FFA), Serum metabolomics, Gas chromatography–flame ionization detection (GC-FID), Fatty acid fingerprinting, Non-metastatic breast cancer, Metabolic biomarkers, Targeted metabolomic profiling
Select article type: Original/Research Article |
Subject:
Molecular Mechanisms
Received: 2025/08/3 | Accepted: 2025/10/7 | ePublished: 2025/10/22
Received: 2025/08/3 | Accepted: 2025/10/7 | ePublished: 2025/10/22
References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394-424. [DOI:10.3322/caac.21492] [PMID]
2. Dieci MV, Orvieto E, Dominici M, Conte P, Guarneri V. Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. The Oncologist. 2014;19(8):805-813. [DOI:10.1634/theoncologist.2014-0108] [PMID] [PMCID]
3. Lukong KE. Understanding breast cancer - The long and winding road. BBA Clinical. 2017;7:64-77. [DOI:10.1016/j.bbacli.2017.04.001] [PMID] [PMCID]
4. Jafari SH, Saadatpour Z, Salmaninejad A, et al. Breast cancer diagnosis: Imaging techniques and biochemical markers. 2018;233(7):5200-13. [DOI:10.1002/jcp.26379] [PMID]
5. Patani N, Martin LA, Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. International Journal of Cancer. 2013;133(1):1-13. doi: 10.1002/ijc.27997 [DOI:10.1002/ijc.27997] [PMID]
6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674. [DOI:10.1016/j.cell.2011.02.013] [PMID]
7. Vo DK, Trinh KTL. Emerging Biomarkers in Metabolomics: Advancements in Precision Health and Disease Diagnosis. International Journal of Molecular Sciences. 2024;25(23). [DOI:10.3390/ijms252313190] [PMID] [PMCID]
8. Fiehn O. Metabolomics by Gas Chromatography-Mass Spectrometry: Combined Targeted and Untargeted Profiling. Current Protocols in Molecular Biology. 2016;114:30.4.1-30.4.32. [DOI:10.1002/cpmb.30] [PMID]
9. Yumba Mpanga A, Siluk D, Jacyna J, et al. Targeted metabolomics in bladder cancer: From analytical methods development and validation towards application to clinical samples. Analytica Chimica Acta. 2018;1037:188-199. [DOI:10.1016/j.aca.2018.07.015] [PMID]
10. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. Cell Metabolism. 2013;18(2):153-161. [DOI:10.1016/j.cmet.2013.05.017] [PMID]
11. Madak-Erdogan Z, Band S, Zhao YC, Smith BP. Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling. Cancer Research. 2019;79(10):2494-2510. [DOI:10.1158/0008-5472.CAN-18-2849] [PMID]
12. Menendez JA, Lupu R. Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opinion on Therapeutic Targets. 2017;21(11):1001-1016. [DOI:10.1080/14728222.2017.1371137] [PMID]
13. Amirjannati N, Asl MA, Hosseini E, et al. Analyzing free fatty acids in seminal plasma from asthenozoospermia patients undergoing antioxidant therapy. JBRA Assisted Reproduction. 2025;29(1):67-75. [DOI:10.5935/1518-0557.20240086] [PMID] [PMCID]
14. Lv W, Yang T. Identification of possible biomarkers for breast cancer from free fatty acid profiles determined by GC-MS and multivariate statistical analysis. Clinical Biochemistry. 2012;45(1-2):127-133. [DOI:10.1016/j.clinbiochem.2011.10.003] [PMID]
15. Tan B, Zhang Y, Zhang T, et al. Identifying potential serum biomarkers of breast cancer through targeted free fatty acid profiles screening based on a GC-MS platform. Biomedical Chromatography. 2020;34(10):e4922. [DOI:10.1002/bmc.4922] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
